Desmopressin

Alternative Names: DDAVP

Desmopressin is a synthetic hormone used to treat certain types of von Willebrand disease (VWD). For patients with type 1 VWD and some with type 2 VWD, desmopressin is the first-line treatment. It works by stimulating the release of stored von Willebrand factor (VWF) and factor VIII (FVIII) from endothelial cells. Desmopressin can be given as an intravenous (IV) infusion, subcutaneous injection, or nasal spray. A desmopressin challenge test is recommended beforehand to assess the patient’s response and ensure it will be effective.

Treatment Type: Prescription Medication

Treatment Class: N/A

Treatment Modality: N/A

Desmopressin

Review Summary

4.5

2 Reviews

Preferred by 2 Reviewers

Based on the provided review, Desmopressin (DDAVP) appears to be a moderately effective treatment for von Willebrand disease. It works by releasing von Willebrand factor from cells near blood vessels, though its effectiveness can vary depending on the patient's cellular stores. The treatment's availability has been limited since a 2020 recall, but production is improving with partnerships and FDA clearance.

This summary was generated by users' reviews

Breakdown by Category

Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.

Cost
4.0
1 = Very Expensive 5 = Very Affordable

4.0

Affordable
Relief Speed
4.0
1 = No Relief 5 = Immediate Relief

4.0

Fast Relief
Side Effects
4.0
1 = Intolerable Effect 5 = No Effect

4.0

Mild Effect
Treatment Line
5.0
1 = Third-line or more 5 = First-line

5.0

First-line

Explore various treatment options to empower yourself in making a well-informed choice.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

4.5

2 Reviews
5
50%
4
50%
3
0%
2
0%
1
0%

AI Summary of User Experiences

Not medical advice.

Based on the provided review, Desmopressin (DDAVP) appears to be a moderately effective treatment for von Willebrand disease. It works by releasing von Willebrand factor from cells near blood vessels, though its effectiveness can vary depending on the patient's cellular stores. The treatment's availability has been limited since a 2020 recall, but production is improving with partnerships and FDA clearance.

Reviews

Filter by reviewer type Pro

Select all Clear all

Cost
Very Expensive
$1000+
Expensive
$501 to $1000
Moderate Cost
$101 to $500
Affordable
$25 to $100
Very Affordable
$25
Relief Speed
No Relief
No noticeable improvement
Slow Relief
Several days to weeks
Moderate Relief
Within 1 - 3 days
Fast Relief
Within hours
Immediate Relief
Within minutes
Side Effect
Intolerable Side Effect
Caused treatment to stop or required hospitalization
Severe Side Effect
Difficult to tolerate, may require intervention
Moderate Side Effect
Noticeable, but manageable
Mild Side Effect
Minor, not bothersome
No Side Effect
Without any adverse effects
Treatment Line
Third-line or more
Used after second-line failed or multiple prior treatment
Second-line
Used after first-line treatment failed or was unsuitable
First-line
First treatment tried
Dr. Curbside

Dr. Curbside

Verified
Physician • Emergency Medicine • How doctors think about decisions — and what real-world experiences add
2 months ago
Desmopressin is first-line therapy for type 1 VWD and some type 2 cases, if the patient is responsive. It requires refrigeration, and among administration routes, IV is most reliable, followed by subcutaneous injection and then nasal spray, which has more variable absorption.
#Affordable #FastRelief #MildEffect #First-line #Rescue/EmergencyUse
View Professional Disclosures
Wsprice

Wsprice

1 year ago
Desmopressin (DDAVP) works by releasing von Willebrand factor stored in cells near blood vessels, but its effect may be limited if cellular stores are low. Availability has been limited since a 2020 recall, though production is improving through partnerships like HFA and STAQ Pharma, with FDA clearance in 48 states. Insurance coverage remains slow to expand.

Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.

We use cookies to personalize our services and provide you with the best possible experience. By continuing to use this site, you agree to this cookie usage. We also use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent. You can learn more about cookies and how your data is processed in the Privacy Policy.

Strictly Necessary Only Accept All